Daromun Shows Promising Results in Reducing Melanoma Recurrence and Metastasis
Source: Ilmattino, July 2024
It is injected directly into the tumor, but its effectiveness has a broader range of action that also prevents the appearance of distant metastases. In cases of locally advanced resectable melanoma, the administration of the immunotherapeutic drug Daromun by Philogen (an Italian-Swiss company), before surgery, reduced the risk of recurrence or death by 41% and reduced the appearance of distant metastases by 40%.
These are the main results of the Pivotal study coordinated by the Schleswig-Holstein University Hospital in Kiel, Germany, and today at the center of the first Innovate Congress – International Neoadjuvant Immunotherapy Across Cancers.
The event, which opens today in Naples, brings together researchers from around the world, engaged in clinical and translational research on neoadjuvant immunotherapy, that is, immunotherapy administered before surgery, with the aim of highlighting clinical aspects, progress, innovative research approaches, as well as collaboration opportunities and possibilities to harmonize approaches across different cancers.